Do analysts prefer QNRX or MLSS?

Milestone Scientific has a consensus price target of $1.00, suggesting a potential upside of 156.41%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer CTSO or QNRX?

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 999.18%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CTSO or QNRX?

In the previous week, Cytosorbents and Cytosorbents both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend POAI or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NMTC or QNRX?

In the previous week, NeuroOne Medical Technologies and NeuroOne Medical Technologies both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend QNRX or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Quoin Pharmaceuticals (QNRX) Competitors

$4.43 -0.13 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 -0.03 (-0.68%)

As of 05:01 PM Eastern

Compare

QNRX vs. MLSS, CTSO, POAI, NMTC, and PETV

Should you buy Quoin Pharmaceuticals stock or one of its competitors? MarketBeat compares Quoin Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quoin Pharmaceuticals include Milestone Scientific (MLSS), Cytosorbents (CTSO), Predictive Oncology (POAI), NeuroOne Medical Technologies (NMTC), and PetVivo (PETV). These companies are all part of the "medical equipment" industry.

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Milestone Scientific has a consensus price target of $1.00, suggesting a potential upside of 156.41%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Quoin Pharmaceuticals has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Milestone Scientific	-52.01%	-60.26%	-40.23%

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Milestone Scientific. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Milestone Scientific's score of 0.67 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Positive
Milestone Scientific	Positive

Milestone Scientific has higher revenue and earnings than Quoin Pharmaceuticals. Milestone Scientific is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Milestone Scientific	$8.90M	3.86	-$6.93M	-$0.05	N/A

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Milestone Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Summary

Milestone Scientific beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Cytosorbents has higher revenue and earnings than Quoin Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.83	-$8.20M	-$0.19	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Quoin Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

In the previous week, Cytosorbents and Cytosorbents both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 999.18%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cytosorbents has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 7.3% of Cytosorbents shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cytosorbents beats Quoin Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quoin Pharmaceuticals has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Quoin Pharmaceuticals' return on equity of -489.85% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Predictive Oncology. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Predictive Oncology's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
Quoin Pharmaceuticals	Positive

Predictive Oncology has higher revenue and earnings than Quoin Pharmaceuticals. Predictive Oncology is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	17.86	-$12.66M	-$13.50	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Quoin Pharmaceuticals beats Predictive Oncology on 8 of the 12 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Quoin Pharmaceuticals has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -98.33% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

In the previous week, NeuroOne Medical Technologies and NeuroOne Medical Technologies both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies has higher revenue and earnings than Quoin Pharmaceuticals. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.47	-$3.61M	-$0.85	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NeuroOne Medical Technologies currently has a consensus target price of $11.67, suggesting a potential upside of 236.22%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Quoin Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to PetVivo?

Quoin Pharmaceuticals (NASDAQ:QNRX) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for PetVivo. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat PetVivo's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Positive
PetVivo	Neutral

Quoin Pharmaceuticals has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Quoin Pharmaceuticals' return on equity of -489.85% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
PetVivo	-902.82%	-4,813.07%	-281.78%

Quoin Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PetVivo has higher revenue and earnings than Quoin Pharmaceuticals. PetVivo is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
PetVivo	$1.05M	24.94	-$10.95M	-$0.38	N/A

Summary

Quoin Pharmaceuticals beats PetVivo on 9 of the 13 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.16M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.15	17.69	22.39	24.18
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	0.28	3.85	9.84	6.72
Net Income	-$15.81M	$75.85M	$3.57B	$337.19M
7 Day Performance	-11.40%	-1.67%	-1.16%	0.48%
1 Month Performance	-28.66%	22.18%	3.85%	5.07%
1 Year Performance	-50.28%	21.83%	27.40%	34.25%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	1.0748 of 5 stars	$4.43 -2.9%	N/A	-47.8%	$9.16M	N/A	N/A	4	News Coverage Gap Up
MLSS Milestone Scientific	1.6013 of 5 stars	$0.38 -3.8%	$1.00 +166.7%	-58.5%	$33.03M	$8.90M	N/A	30	Gap Down
CTSO Cytosorbents	1.8095 of 5 stars	$0.51 +6.3%	$5.38 +953.9%	-44.1%	$32.03M	$37.20M	N/A	220	News Coverage High Trading Volume
POAI Predictive Oncology	N/A	$8.76 +20.7%	N/A	-49.1%	$29.73M	$1.66M	N/A	30
NMTC NeuroOne Medical Technologies	2.4531 of 5 stars	$3.44 -3.4%	$11.67 +239.1%	+0.1%	$29.65M	$12.10M	N/A	20	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. MLSS, CTSO, POAI, NMTC, and PETV

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Summary

How does Quoin Pharmaceuticals compare to Predictive Oncology?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Summary

How does Quoin Pharmaceuticals compare to PetVivo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. MLSS, CTSO, POAI, NMTC, and PETV

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Do analysts prefer QNRX or MLSS?

Is QNRX or MLSS more profitable?

Does the media prefer QNRX or MLSS?

Which has preferable valuation & earnings, QNRX or MLSS?

Do insiders & institutionals hold more shares of QNRX or MLSS?

Which has more volatility and risk, QNRX or MLSS?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Which has stronger earnings and valuation, CTSO or QNRX?

Is CTSO or QNRX more profitable?

Does the media prefer CTSO or QNRX?

Do analysts prefer CTSO or QNRX?

Which has more risk & volatility, CTSO or QNRX?

Do insiders and institutionals hold more shares of CTSO or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Predictive Oncology?

Do insiders and institutionals hold more shares of POAI or QNRX?

Which has more volatility and risk, POAI or QNRX?

Do analysts recommend POAI or QNRX?

Is POAI or QNRX more profitable?

Does the media prefer POAI or QNRX?

Which has higher valuation and earnings, POAI or QNRX?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Is NMTC or QNRX more profitable?

Does the media prefer NMTC or QNRX?

Which has stronger earnings & valuation, NMTC or QNRX?

Do insiders & institutionals hold more shares of NMTC or QNRX?

Do analysts recommend NMTC or QNRX?

Which has more risk & volatility, NMTC or QNRX?

Summary

How does Quoin Pharmaceuticals compare to PetVivo?

Does the media refer more to QNRX or PETV?

Is QNRX or PETV more profitable?

Which has more risk & volatility, QNRX or PETV?

Do analysts recommend QNRX or PETV?

Do insiders & institutionals have more ownership in QNRX or PETV?

Which has higher earnings & valuation, QNRX or PETV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools